Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) – Investment analysts at Roth Capital issued their FY2029 earnings per share estimates for shares of Aptevo Therapeutics in a research note issued on Monday, February 17th. Roth Capital analyst J. Aschoff anticipates that the biotechnology company will post earnings per share of $2.84 for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($85.96) per share.
Separately, StockNews.com assumed coverage on Aptevo Therapeutics in a report on Monday, December 9th. They issued a “sell” rating for the company.
Aptevo Therapeutics Trading Up 4.5 %
NASDAQ APVO opened at $3.49 on Wednesday. Aptevo Therapeutics has a fifty-two week low of $3.01 and a fifty-two week high of $399.60. The stock has a 50 day simple moving average of $4.65 and a two-hundred day simple moving average of $241.74.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- How to Profit From Growth Investing
- Affirm Hits Profitability—Here’s What Investors Should Watch
- Do ETFs Pay Dividends? What You Need to Know
- There’s Room to Chase These 3 Stocks Trading Near 52-Week Highs
- With Risk Tolerance, One Size Does Not Fit All
- 3 Stocks With Robust Growth Outlooks Insiders Are Buying
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
